CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Intersect ENT Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Intersect ENT Inc
1555 Adams Dr
Phone: (650) 641-2100p:650 641-2100 MENLO PARK, CA  94025-1439  United States Fax: (302) 636-5454f:302 636-5454
This company was Merged or Acquired on 5/13/2022.
This company ceased filing statements with the SEC on 5/23/2022.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Intersect ENT, Inc. is a global ear, nose, and throat (ENT) medical technology company. The Company's steroid-releasing products are designed to provide mechanical spacing and deliver targeted therapy (mometasone furoate) to the site of disease. These products include its PROPEL family of products (PROPEL, PROPEL Mini and PROPEL Contour) and the SINUVA (mometasone furoate) Sinus Implant. The PROPEL family of products are used in adult patients to reduce inflammation and maintain patency following sinus surgery, primarily in hospitals and ambulatory surgery centers (ASC), with increasing applications in the physician office setting of care in conjunction with balloon dilation and following post-surgical debridement. SINUVA is a physician administered drug, designed to be used in the physician office setting of care to treat adult patients who have had ethmoid sinus surgery yet suffer from recurrent sinus obstruction due to polyps. It also offers ENT products, such as VenSure and CUBE.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202212/31/2021YesYes--Yes

Industries
SIC Code Description
3841 Surgical and medical instruments and apparatus
3842 Orthopedic, prosthetic, and surgical appliances and supplies

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent chairman of the Board Kieran T.Gallahue 58 5/1/2020 4/9/2015
President, Chief Executive Officer, Director Thomas A.West 57 7/24/2019 7/22/2019
Chief Financial Officer, Executive Vice President Richard A.Meier 62 11/26/2019 11/26/2019
7 additional Officers and Directors records available in full report.

Business Names
Business Name
Fiagon AG Medical Technologies
Sinexus Inc.
XENT

General Information
Number of Employees: 433 (As of 12/31/2021)
Outstanding Shares: 33,813,722 (As of 4/27/2022)
Shareholders: 12
Stock Exchange: NASD
Federal Tax Id: 200280837
Fax Number: (302) 636-5454
Email Address: info@intersectENT.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, March 23, 2024